In a significant development affecting the biotech industry, WuXi AppTec, a leading Chinese manufacturing company, has reported a revenue decline for the first half of 2024. This downward trend coincides with growing concerns about the impending BIOSECURE Act, which aims to restrict U.S.
Arch Venture Partners has announced the closing of their 13th venture fund, known as "Fund XIII," amounting to over $3 billion. This milestone signifies a major revitalization in the biotech investment landscape, targeting the growth and development of early-stage biotechnology companies.
Uganda’s Leader of Opposition, Joel Ssenyonyi, alongside a group of 15 other Members of Parliament, recently conducted an insightful inspection of the Dei BioPharma facility located in Matugga. This visit, which took place on September 19, 2024, marked a significant milestone that underscored the f
Recent advancements in cancer treatments have provided new hope for patients, with significant progress showcased in the biopharmaceutical industry. The interim results of ArriVent BioPharma, Inc.'s Phase 1b FURTHER trial for their drug firmonertinib have been particularly promising. This
The ongoing evolution and novel advancements in filtration technology are essential for biologics manufacturing, as the complexity and size of therapeutic modalities increase. This evolution has introduced new challenges that require efficient and effective filtration systems to ensure the
The landscape of biopharmaceutical research and development (R&D) has seen a remarkable evolution, particularly in the realm of oncology. In recent years, a significant portion of R&D investments has been channeled into cancer research, paving the way for groundbreaking treatments and
In a significant move reflecting the growing regulatory pressure on data security practices, Enzo Biochem has reached a settlement with the Attorneys General of Connecticut, New York, and New Jersey over allegations of inadequate security measures leading to a data breach earlier this year. The
Bora Pharmaceuticals continues its robust expansion by acquiring a significant operational stake in Tanvex BioPharma, a deal set to close in early 2025. This strategic acquisition positions Bora as the largest shareholder in Tanvex, granting the company access to a commercial-scale production
U.S. lawmakers are raising alarms about clinical trials conducted in China, specifically those affiliated with the Chinese military or located in the Xinjiang Uyghur Autonomous Region. This heightened vigilance is poised to dramatically impact how the U.S. FDA scrutinizes data from these trials.
Recent research breakthroughs have revealed an intriguing and unexpected benefit of certain cancer drugs: the potential to protect against Alzheimer's disease. Originally developed for combating cancer, these medications have shown promise in preventing Alzheimer's in animal models such
